Mielke, Michelle M.Dage, Jeffrey L.Frank, Ryan D.Algeciras-Schimnich, AliciaKnopman, David S.Lowe, Val J.Bu, GuojunVemuri, PrashanthiGraff-Radford, JonathanJack, Clifford R., Jr.Petersen, Ronald C.2023-10-232023-10-232022Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community [published correction appears in Nat Med. 2022 Oct 10;:]. Nat Med. 2022;28(7):1398-1405. doi:10.1038/s41591-022-01822-2https://hdl.handle.net/1805/36557Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both amyloid and tau pathology in clinical settings, but their performance in heterogeneous community-based populations is unclear. We examined P-tau181 and P-tau217 (n = 1,329, aged 30-98 years), in the population-based Mayo Clinic Study of Aging. Continuous, unadjusted plasma P-tau181 and P-tau217 predicted abnormal amyloid positron-emission tomography (PET) (area under the receiver operating characteristic curve (AUROC) = 0.81-0.86) and tau PET entorhinal cortex (AUROC > 0.80), but was less predictive of a tau PET temporal region of interest (AUROC < 0.70). Multiple comorbidities were associated with higher plasma P-tau181 and P-tau217 levels; the difference between participants with and without chronic kidney disease (CKD) was similar to the difference between participants with and without elevated brain amyloid. The exclusion of participants with CKD and other comorbidities affected the establishment of a normal reference range and cutpoints. Understanding the effect of comorbidities on P-tau181 and P-tau217 levels is important for their future interpretation in the context of clinical screening, diagnosis or prognosis at the population level.en-USPublisher PolicyAlzheimer diseaseAmyloidosisBiomarkersPositron-emission tomographyChronic renal insufficiencyArticle